Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?
作者信息
Coombes Ian D, Legg Amy, Patterson Tina, Kelly Tanya, Henderson Andrew, Roberts Jason A
机构信息
Department of Pharmacy, Royal Brisbane and Women's Hospital.
Department of Pharmacy, University of Queensland, Brisbane.
出版信息
Aust Prescr. 2022 Apr;45(2):67-68. doi: 10.18773/austprescr.2022.021. Epub 2022 Mar 24.
Abstract
摘要
相似文献
1
Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?用于治疗轻至中度新冠肺炎的口服抗病毒药物：是万灵药还是后勤与临床难题？
Aust Prescr. 2022 Apr;45(2):67-68. doi: 10.18773/austprescr.2022.021. Epub 2022 Mar 24.
2
Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19.莫努匹拉韦和奈玛特韦-利托那韦与轻度至中度COVID-19高危患者的可预防死亡率、住院率及相关可避免的医疗系统成本的关联
Lancet Reg Health West Pac. 2023 Jan;30:100602. doi: 10.1016/j.lanwpc.2022.100602. Epub 2022 Oct 5.
3
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?口服奈玛特韦/利托那韦治疗新冠病毒病：黑暗中的曙光？
Antibiotics (Basel). 2022 Feb 9;11(2):220. doi: 10.3390/antibiotics11020220.
4
Efficacy and safety of oral antivirals in individuals aged 80 years or older with mild-to-moderate COVID-19: preliminary report from an Italian Prescriber Center.口服抗病毒药物治疗80岁及以上轻至中度COVID-19患者的疗效和安全性：来自意大利一个处方中心的初步报告。
Infez Med. 2022 Dec 1;30(4):547-554. doi: 10.53854/liim-3004-9. eCollection 2022.
5
Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.莫努匹拉韦——一种新型口服抗SARS-CoV-2药物。
Antibiotics (Basel). 2021 Oct 23;10(11):1294. doi: 10.3390/antibiotics10111294.
6
Molnupiravir, an Oral Antiviral Treatment for COVID-19.莫努匹拉韦，一种用于治疗新冠肺炎的口服抗病毒药物。
medRxiv. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639.
7
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination.严重急性呼吸综合征冠状病毒2型奥密克戎变种对莫努匹拉韦、奈玛特韦及二者联用高度敏感。
Cell Res. 2022 Mar;32(3):322-324. doi: 10.1038/s41422-022-00618-w. Epub 2022 Jan 20.
8
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.莫努匹拉韦对新型冠状病毒肺炎的抗病毒活性：证据的简要综述
Bull Natl Res Cent. 2022;46(1):62. doi: 10.1186/s42269-022-00753-9. Epub 2022 Mar 10.
9
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.加利福尼亚州 2021 年 12 月至 2022 年 5 月辉瑞公司新冠口服药 Paxlovid 治疗后因 COVID-19 住院和急诊就诊情况。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
10
Can help control cytokine storm in COVID-19?能否有助于控制新冠病毒疾病中的细胞因子风暴？
J Ginseng Res. 2022 May;46(3):337-347. doi: 10.1016/j.jgr.2022.02.006. Epub 2022 Feb 25.
本文引用的文献
1
Pandora's box: Paxlovid, prescribing, pharmacists and pandemic.潘多拉魔盒：帕罗韦德、处方开具、药剂师与大流行
J Pharm Pract Res. 2022 Feb;52(1):1-4. doi: 10.1002/jppr.1799. Epub 2022 Feb 10.
2
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
3
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
4
Vaccine Effectiveness Studies in the Field.现场疫苗效力研究
N Engl J Med. 2021 Aug 12;385(7):650-651. doi: 10.1056/NEJMe2110605. Epub 2021 Jul 21.
5
Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review.COVID-19 治疗药物与抗精神病药物的药物相互作用：来自 4 个数据库的综合证据和系统评价。
Psychopharmacology (Berl). 2021 Feb;238(2):329-340. doi: 10.1007/s00213-020-05716-4. Epub 2021 Jan 7.
6
Fast-tracking of new drugs: getting the balance right.新药快速审批：把握好平衡
Aust Prescr. 2018 Aug;41(4):98-99. doi: 10.18773/austprescr.2018.032. Epub 2018 Aug 1.
Zotero 插件